Consort Medical plc’s “Sell” Rating Reaffirmed at FinnCap (CSRT)
Consort Medical plc (LON:CSRT)‘s stock had its “sell” rating reaffirmed by investment analysts at FinnCap in a note issued to investors on Tuesday. They currently have a GBX 690 ($11.71) target price on the stock. FinnCap’s price objective indicates a potential downside of 21.59% from the company’s current price.
Shares of Consort Medical plc (LON:CSRT) traded down 0.94% on Tuesday, hitting GBX 871.77. 192,075 shares of the company’s stock traded hands. Consort Medical plc has a 1-year low of GBX 773.00 and a 1-year high of GBX 1113.00. The stock’s 50-day moving average is GBX 878.3 and its 200-day moving average is GBX 942.6. The company’s market cap is £250.8 million.
The company also recently declared a dividend, which is scheduled for Friday, October 24th. Shareholders of record on Wednesday, September 17th will be given a dividend of GBX 13.35 ($0.23) per share. This represents a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, September 17th.
A number of other analysts have also recently weighed in on CSRT. Analysts at Numis Securities Ltd reiterated an “add” rating on shares of Consort Medical plc in a research note on Thursday, June 12th. They now have a GBX 940 ($15.96) price target on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Consort Medical plc in a research note on Wednesday, June 11th. They now have a GBX 1,044 ($17.72) price target on the stock. Finally, analysts at Westhouse Securities reiterated a “buy” rating on shares of Consort Medical plc in a research note on Friday, June 6th. They now have a GBX 1,100 ($18.67) price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of GBX 942.50 ($16.00).
Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.